Agios' anemia drug hits goal in phase 3, teeing up 2021 filing

A phase 3 trial of Agios Pharmaceuticals’ mitapivat in a form of anemia has met its primary endpoint. The success gives Agios some of the data it needs to file for approval of the drug in pyruvate kinase (PK) deficiency next year.